Growth Metrics

Amneal Pharmaceuticals (AMRX) Accumulated Expenses (2018 - 2019)

Amneal Pharmaceuticals has reported Accumulated Expenses over the past 2 years, most recently at $29.0 million for Q4 2019.

  • Quarterly results put Accumulated Expenses at $29.0 million for Q4 2019, up 22.55% from a year ago — trailing twelve months through Dec 2019 was $29.0 million (up 22.55% YoY), and the annual figure for FY2019 was $29.0 million, up 22.55%.
  • Accumulated Expenses for Q4 2019 was $29.0 million at Amneal Pharmaceuticals, up from $23.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for AMRX hit a ceiling of $29.0 million in Q4 2019 and a floor of $23.6 million in Q4 2018.